DEV Community: Rabiel Amirian

Drug safety signals that surface in the dental chair first

Rabiel Amirian — Mon, 26 Oct 2026 16:37:05 +0000

For: pharma safety, pharmacovigilance, HEOR, RWE, payer, and AI teams working with commercial real world data
From: Rabiel Amirian, DDS, Founder, Bridge Health Syndicate
Site: https://bhsyndicate.com
Contact: dra@bhsyndicate.com

Every safety team knows the drugs with oral consequences. Antiresorptives and osteonecrosis of the jaw. Calcium channel blockers, cyclosporine, and phenytoin with gingival overgrowth. Anticholinergic load and the dry mouth that turns into rampant caries. Checkpoint inhibitors with lichenoid and mucosal reactions. Chemotherapy with mucositis and infection risk that decides whether a cycle runs on time.

The label lists these effects. The protocol names them. Then the analyst opens the data and discovers that the place these events are first seen, documented, and treated is not in the dataset at all.

Oral adverse events do not start in the hospital. They start in the dental chair. Medical records catch the ones that escalate. Everything before that is invisible to a medical only stack.

Here are five questions safety and outcomes teams are writing into protocols now, and why each one depends on dental data linked to the same patient timeline as the prescription.

1. When did the oral event actually begin?

Time to onset is the backbone of any causality assessment. For jaw osteonecrosis, the first documented sign is usually exposed bone, a nonhealing extraction site, or unexplained pain noted by a dentist. The medical claim, if one appears at all, arrives weeks or months later when the case reaches an oral surgeon or a hospital.

A medical only dataset therefore records onset late and records it selectively. The cases that resolve under dental management never generate the code you are searching for. Your incidence is biased toward severe cases, and your time to onset distribution is shifted right by however long the dental phase lasted.

With dental events on the same timeline, onset is the chairside finding, not the referral.

2. What happened in the mouth before the first dose?

Several oral safety questions turn on baseline. Was there an extraction in the months before antiresorptive therapy began? Was periodontal disease already advanced before an immunosuppressant started? Was a patient cleared dentally before radiation or chemotherapy, or did treatment begin with an active infection?

These are not covariates you can impute. They are dated clinical events that either sit in the record or do not. Without them, a study cannot separate drug effect from pre existing oral disease, and a reviewer will say so.

Linked dental history turns baseline oral status from an assumption into an observation.

3. Is the signal real, or is it a dental access artifact?

Oral events are reported more often in populations that see a dentist regularly, simply because someone is looking. A disproportionality signal in spontaneous reports, or an elevated rate in a claims cohort, can reflect who has dental coverage rather than what the drug does.

The only clean way to adjust for surveillance intensity is to observe it: recall cadence, exam frequency, and time since last dental visit for every patient in both arms. Medical data cannot see any of that. Dental data unlinked to the medical record cannot connect it to exposure.

A safety signal you cannot adjust for ascertainment is a hypothesis, not a finding.

4. Did a dental intervention prevent the event you are measuring?

Many oral adverse events are preventable. Pre treatment dental clearance, fluoride programs for patients on xerogenic medications, periodontal maintenance during immunosuppression. If those interventions happen, outcomes improve. If your data cannot see them, the protective effect disappears into the noise, or worse, gets attributed to the drug.

This matters for more than safety. Risk management programs, label language around dental examination, and payer coverage of preventive dental care for high risk therapies all depend on showing that the intervention works. That evidence requires the intervention and the outcome on the same person.

5. What did the event cost, and who paid for it?

Oral complications of systemic therapy carry real cost: emergency visits, hospital admissions for infection, delayed or abandoned treatment cycles, extractions, prosthetic replacement. Some of that cost lands in medical claims. Much of it lands in dental charges that sit outside the medical spend line entirely.

A total cost model that only sees the medical side understates the burden and overstates the value of any program that shifts care into the dental setting. Payers modeling coverage for preventive dental services in high risk populations need both sides joined at the person level, or the business case never closes.

Why buyers keep hitting this wall

None of these questions is exotic. Each one is a standard element of a safety study, a risk management evaluation, or a cost of illness model. The obstacle is structural. Dental care is delivered, documented, and billed in a separate system from medicine. Commercial real world data was assembled from the medical side. The mouth was left out by default, and coverage maps still show it as a thin column or a blank.

The market is putting real prices on depth. A public filing last week disclosed a buyer paying $100 per delivered de identified record in a single therapeutic area, plus exclusivity. That is what buyers pay when a dataset answers questions others cannot. Oral safety evidence sits in exactly that category: high value questions, almost no supply.

What Bridge Health Syndicate operates

Bridge Health Syndicate operates the member governed dental data layer for healthcare. Contributing dental organizations set research use policy and approve partner categories. De identified dental records link to medical records at the patient level through the HELIX Protocol (patent pending). Identity never crosses the boundary.

For safety and outcomes teams, that means chairside findings, procedures, and visit cadence sit on the same de identified patient timeline as prescriptions, diagnoses, and medical utilization. Onset is observed where it happens. Baseline oral status is documented. Surveillance intensity is measurable. Preventive dental care is visible as an intervention. Dental and medical cost meet in one model.

Questions to put to any data source

Before you commit a safety protocol with oral endpoints to a dataset, ask:

Where is the first documented sign of the oral event recorded, and is it in this data?

Can I see dated dental procedures in the twelve months before first exposure?

How do I measure dental visit frequency to adjust for ascertainment?

Are preventive dental interventions observable as exposures in their own right?

Can dental charges and medical claims be joined for the same person?

If the honest answer to most of these is no, the oral safety profile in your study is being drawn from its most severe tail.

Soft next step

The oral consequences of systemic therapy are documented every day in dental charts. The evidence teams need has always existed. It now sits on a linked patient timeline.

For the data brief on the Bridge Health Syndicate linked dental medical layer, visit https://bhsyndicate.com or email dra@bhsyndicate.com.

Rabiel Amirian, DDS
Founder, Bridge Health Syndicate
https://bhsyndicate.com
dra@bhsyndicate.com

Dental data has a supply problem. Supply follows governance.

Rabiel Amirian — Mon, 19 Oct 2026 15:18:33 +0000

For: pharma, biotech, payer, device, and AI teams buying real world data
From: Rabiel Amirian, DDS, Founder, Bridge Health Syndicate
Site: https://bhsyndicate.com
Contact: dra@bhsyndicate.com

Most buyers assume the hard part of oral systemic evidence is technical. Linkage, tokenization, normalization, de identification. Those problems are real, and they are solved problems for anyone willing to do the work.

The harder problem sits upstream. Dental records live inside practices and dental organizations that have never been asked, in a serious way, to become research data sources. Until they agree to contribute, and keep agreeing for years, no amount of buyer budget produces a longitudinal oral systemic dataset.

Dental RWD does not have a demand problem. It has a supply problem. And supply follows governance.

Why the charts never reach your stack

Dentistry documents a remarkable amount of clinical detail. Periodontal charting, radiographs, restorative history, infection, tooth loss, medication lists taken chairside, recall cadence over many years. Almost none of it reaches commercial real world data as a first class signal.

The reason is not that dental organizations are unaware of the value. The reason is that the default offer to them has been unattractive. Historically, dental data reached the market one of three ways: silently through a billing intermediary, through a one time extract sold without the provider understanding the downstream use, or through a vendor relationship where the provider handed over records and lost visibility the moment the file left the building.

Every one of those paths teaches providers the same lesson. Contribution is extractive, opaque, and irreversible. Rational operators respond by saying no, or by saying yes once and never again.

For buyers, that history explains the thin dental column on every coverage map. It also explains why the dental sources that do exist tend to be shallow, short, and fragile.

What contributors actually need

Dental organizations that run multiple locations are sophisticated businesses. They have compliance teams, payer contracts, and boards. When they evaluate a data program, they ask the same questions any institutional data owner asks.

Who decides which research uses are permitted? Which partner categories can access derived data, and which cannot? Where does patient identity live, and does it ever leave our control? What do we see after a study starts? What happens if we want to change the terms, or leave?

A program that cannot answer those questions in writing does not get contribution from serious operators. A program that answers them with "trust us" gets contribution from a few, briefly.

The answers that work share a pattern. Contributors hold a formal seat in research use policy. Partner categories are defined in advance rather than negotiated deal by deal behind their backs. Identity stays on the provider side of a documented boundary. Economic participation is structured rather than incidental. Withdrawal rules are explicit, so staying is a choice rather than a trap.

Those are not concessions. They are the conditions under which supply becomes durable.

Why this matters to the buyer

It is tempting to treat contributor governance as the vendor's internal business. It is not. It shows up directly in the evidence you buy.

Continuity. Oral systemic questions are longitudinal by nature. Periodontal disease course, tooth loss after systemic therapy, infection risk before transplant or joint replacement, adherence signals across years. If the sources feeding your series can leave without warning, your study inherits that risk. Governed contribution is what keeps a five year series intact in year four.

Depth. Providers who understand and control the use of their data are willing to contribute richer data. Clinical texture beyond billing codes comes from contributors who trust the program, not from intermediaries passing along what they happen to hold.

Defensibility. Regulators, privacy reviewers, ethics boards, and journal referees increasingly ask where data came from and under what terms. Buyers are being trained to inspect cohort logic and provenance, not just accept a patient count. A dataset whose contributors consented to research use under documented policy is easier to stand behind than one assembled from silent upstream flows.

Reproducibility. When contribution rules are stable, the same cohort definition run next year draws from the same governed base. That is what lets evidence generation teams rerun, refresh, and extend work rather than rebuild it.

None of this appears on a field list. All of it determines whether the field list is worth anything eighteen months from now.

The founding cohort model

Bridge Health Syndicate was designed from the supply side first.

We built the member governed dental data layer for healthcare. Contributing dental organizations join as members. Members set research use policy and approve partner categories. De identified dental records link to medical records at the patient level through the HELIX Protocol (patent pending), and identity never crosses the boundary. Buyers get longitudinal oral systemic signal. Members keep control of how their data is used.

The founding member cohort matters for a specific reason. The organizations that shape the governance model at the start are the ones whose data forms the longitudinal base every later study draws on. Their participation is structured as membership with a voice in the rules, not as a vendor transaction, which is precisely why it is built to last.

We do not disclose who holds founding seats. That discretion is part of the governance model, and it is one of the reasons serious operators engage. What buyers can evaluate is the architecture: how policy is set, how partner categories are approved, where identity lives, and how continuity is protected.

Questions to ask any dental data source

Before you license dental or oral systemic data from anyone, ask about supply as carefully as you ask about schema.

Who are the contributors, by type, and what formal role do they hold in research use decisions?

Were contributors told, in writing, which categories of partners can use derived data?

Where is patient identity held, and has it ever left the contributing organization?

What contractual protection exists for longitudinal continuity if a contributor changes its mind?

How does the source add new contributors without changing the rules for existing ones?

A vendor who answers with architecture is offering supply that will still be there when your study ends. A vendor who answers with volume is offering whatever happened to flow through last quarter.

Soft next step

The oral systemic signal buyers want has always existed. What was missing was a supply model dental organizations would actually join. That model now operates.

For the data brief on the Bridge Health Syndicate linked dental medical layer, visit https://bhsyndicate.com or email dra@bhsyndicate.com.

Rabiel Amirian, DDS
Founder, Bridge Health Syndicate
https://bhsyndicate.com
dra@bhsyndicate.com

The persistent key problem: linkage design is now a buyer diligence question

Rabiel Amirian — Mon, 05 Oct 2026 17:41:52 +0000

Every longitudinal dataset rests on one quiet engineering decision: how a patient is followed over time without being exposed.

For years buyers treated that decision as the vendor's problem. A token appeared, records joined, the license was signed. In late September a European regulator made it the buyer's problem too.

A €7 million reminder

On September 23, 2026, Italy's data protection authority, the Garante, fined a major RWD vendor €7 million over a database built from the records of about one million patients of roughly 800 general practitioners. The company described the data as anonymous. The Garante disagreed. According to the authority, the code assigned to each patient made it possible to follow that patient over time, and combined with detailed clinical and location data, it allowed individuals to be singled out and, with reasonable means, reidentified. The authority also treated the company as controller from the point of collection, because it directed how pseudonymization happened at the source.

The decision can be appealed, it concerns one dataset, and European law is not HIPAA. None of that makes it irrelevant to a US buyer. It names the central tension in real world evidence plainly: the feature that makes data valuable for research, a persistent link across time, is the same feature regulators examine first.

The tension buyers cannot outsource

Research needs continuity. A protocol that measures exposure, endpoint, and confounders across years needs to know that the record in year one and the record in year four belong to the same person. Without that, there is no cohort, only a pile of events.

Privacy needs distance. The more detail that rides alongside a persistent identifier, the shorter the path back to a real person. Diagnoses, prescriptions, visit dates, geography: each one makes a study more useful and a dataset more identifiable.

Most vendors resolve this tension in a deck. Few resolve it in architecture. When the architecture fails, the consequences land on everyone in the chain: the source who contributed, the vendor who assembled, and the sponsor whose study now depends on a dataset under scrutiny.

Why dental makes this sharper

Dental data adds a layer most RWD diligence has never had to examine.

Dental records are rich, longitudinal, and highly specific. Tooth level charting, periodontal measurements, imaging, recall intervals, and procedure histories are exactly the depth that makes oral systemic research possible. They are also distinctive. A full chart history is not a generic claims row.

Dental records also live in a different place. They sit in practice management systems that were never connected to hospital networks, never routed through medical clearinghouses, and rarely touched by the tokenization pipelines medical data runs through. Linking them to medical records is not a matter of flipping a switch on an existing token. It requires deliberate design of where identity lives, who holds it, and what crosses into the research environment.

Shortcuts are tempting. Move identifiers to a central location, match them, strip them later. That approach produces a join quickly. It also produces a central point that knows who everyone is, which is precisely what a careful buyer should not want sitting underneath a study.

Five diligence questions about the identity boundary

Before licensing any linked dataset, dental or otherwise, ask the vendor to answer these in writing:

Where does identity live, and who holds it? Name the system and the party. "Encrypted" is not an answer.
What crosses into the research environment? List the fields. If a persistent code travels with dense clinical and location detail, ask how reidentification risk was assessed and by whom.
Who directs the de identification process at the source? The Italian decision turned partly on this. Control at the source carries responsibility for the chain.
Can the linkage be explained to a contributing provider in one paragraph? If sources do not understand how their patients are protected, their continued participation is a risk to your longitudinal series.
What happens to your study if a source withdraws? Datasets assembled without provider governance can lose contributors overnight. That breaks the very continuity you paid for.

A vendor that answers crisply is selling an asset. A vendor that answers with adjectives is selling exposure.

What Bridge Health Syndicate built

Bridge Health Syndicate built the member governed dental data layer for healthcare with the identity boundary as the starting design constraint, not a compliance patch.

De identified dental records link to medical records at the patient level through the HELIX Protocol (patent pending). Identity never crosses the boundary. The research environment receives what research needs, the longitudinal oral systemic signal, without becoming a place that knows who patients are.

Governance follows the same logic. Contributing dental organizations are members, not silent upstream sources. They set research use policy and partner categories, and they keep control of how their data is used. That matters to buyers for a commercial reason as much as an ethical one: providers who understand and govern the linkage stay in the network, and longitudinal series stay intact.

The result is linked dental medical evidence designed to survive diligence, not just pass a demo.

The question behind the question

The Garante decision will be read closely across Europe, and US privacy teams will read it too. The lesson for buyers is not that linked data is dangerous. It is that linkage design is now part of what you are buying.

The mouth has been missing from real world evidence for a long time. Adding it back the wrong way would trade one gap for another. Adding it back with identity on the right side of the boundary is how oral systemic research becomes a durable asset.

For the data brief on the Bridge Health Syndicate linked dental medical layer, visit https://bhsyndicate.com or email dra@bhsyndicate.com.

—

Rabiel Amirian, DDS

Founder, Bridge Health Syndicate

https://bhsyndicate.com

dra@bhsyndicate.com

Five protocol questions your dental free RWD stack cannot answer

Rabiel Amirian — Mon, 28 Sep 2026 16:45:17 +0000

Most RWD diligence still ends with a coverage map: claims yes, labs yes, EHR fragments maybe, dental blank or thin. That map looks complete until someone writes the actual protocol.

Then the room goes quiet. The question on the whiteboard is precise. The stack on the renewal invoice cannot support it.

Below are five protocol questions buyers keep writing into study outlines, statistical analysis plans, and evidence strategy decks. Each one is answerable in principle. Each one collapses when the mouth is missing from the person level link graph.

1. Can you define exposure using dental procedure timing on the same patient timeline as medical care?

A protocol that treats periodontal therapy, extraction, or infection clearance as an exposure needs date stamped dental events joined to the medical timeline. Not a separate dental extract. Not a hand waved propensity model that pretends billing spikes are treatment courses.

Medical only stacks force you into soft proxies: antibiotics that could mean anything, vague infection codes that lag the chairside event, or complete omission of the dental episode. Exposure windows drift. Immortal time creeps in. Sensitivity analyses multiply because the primary definition was never observed.

If your vendor cannot show dental procedures as first class events on the same de identified patient spine as medical encounters, you do not have an exposure definition. You have a workaround.

2. Can you ascertain oral endpoints before the medical claim records the fallout?

Oncology supportive care, transplant prep, anticoagulation, and diabetes programs often need oral infection, tooth loss, and failed restorative care as endpoints or intermediate outcomes. Those signals live in dental charts long before a hospital claim codes abscess, sepsis, or emergency extraction fallout.

When you only see the medical aftermath, you measure late. You miss the preventable window. You undercount events that never escalate into a medical code. Safety and outcomes work that depends on oral endpoints then becomes a study of severe cascades, not of the oral disease course itself.

Research grade oral systemic work needs the dental endpoint, not only the medical echo.

3. Can you adjust for oral disease burden as a confounder or effect modifier?

Cardiometabolic, cardiovascular, and maternal outcomes research repeatedly brushes against inflammation, nutrition, and infection load. Periodontal disease severity and untreated oral infection are not decorative covariates. They change who enters a pathway, who stays adherent, and who experiences downstream medical utilization.

Without linked dental depth, analysts drop the variable, use a weak claims proxy, or wave at residual confounding in the limitations section. Regulators and internal reviewers notice. So do competitors who can show cleaner adjustment sets.

A stack that cannot grade oral disease burden at the person level cannot honestly claim control for one of the most visible chronic inflammatory conditions in adult medicine.

4. Can you observe supportive dental care across a systemic therapy course?

Protocols for oncology, rheumatology, and other long course therapies often assume supportive care pathways that include dental clearance, infection monitoring, and post treatment oral recovery. The medical record may note a referral. It rarely captures whether the dental work happened, when it happened, or what was found.

That gap breaks adherence narratives, toxicity attribution, and quality of supportive care analyses. Teams end up studying intention to refer rather than receipt of care. Device and drug programs that touch mucosal or infection risk feel this acutely.

Longitudinal dental events on the linked patient timeline turn a referral footnote into an observable pathway.

5. Can you connect untreated oral disease to medical utilization with person level continuity?

Payers and HEOR teams want total cost and avoidable utilization models that include oral disease as a driver, not as a siloed dental spend line. That requires untreated disease and dental treatment intensity joined to medical utilization for the same person over time.

Unlinked dental dumps cannot do this. Dual eligibility guesses cannot do this cleanly. Post hoc fuzzy matches that never survive diligence cannot do this at scale.

Without person level continuity, you get correlation theater: dental rates in one file, medical rates in another, and a slide that hopes the populations overlap. Decision makers are done buying that story.

What these five questions really test

None of the five is a request for more dashboards. Each one tests whether dental is inside the identity resolved evidence graph or sitting outside it as commodity filler.

Ask your current vendors out loud:

Where do dental procedure dates sit on the patient timeline?
How are oral endpoints ascertained, not merely inferred from late medical codes?
How is oral disease burden available for confounding and effect modification?
Can supportive dental care be observed across a therapy course?
Can untreated oral disease join medical utilization with person level continuity?

If the answers rely on roadmap language, optional modules, or a second silo you are expected to join later, the protocol questions above are not answerable today.

What Bridge Health Syndicate operates

Bridge Health Syndicate operates a member governed dental data layer for healthcare. De identified dental records are linked to medical records at the patient level through the HELIX Protocol (patent pending). Identity never crosses the boundary. Members keep control.

Buyers pay for linked real world evidence. Founding contributors own a piece of the asset. That structure exists so research questions like the five above stop dying in diligence.

Dental free stacks will keep winning renewals that only check box coverage. They will keep failing protocols that need the mouth on the same person timeline as the rest of medicine.

If you want the data brief on the linked dental medical layer, visit https://bhsyndicate.com or email dra@bhsyndicate.com.—Rabiel Amirian, DDS
Founder, Bridge Health Syndicate
https://bhsyndicate.com
dra@bhsyndicate.com

Why your RWD still misses the mouth

Rabiel Amirian — Mon, 28 Sep 2026 04:57:38 +0000

Half of American adults see a dentist every year. Almost none of what happens in that chair reaches the datasets you buy.

That is not a small omission. It is a structural blind spot in how the industry builds evidence.

The quiet failure in "complete" RWD

Most commercial real world data stacks are strong on medical claims, pharmacy, labs, and increasingly on EHR fragments. They are weak to empty on longitudinal dental care.

Yet the mouth is not a side quest. Periodontal disease, tooth loss, chronic oral infection, and the procedures that follow sit in the causal neighborhood of diabetes control, cardiovascular risk, pregnancy outcomes, oncology supportive care, and drug safety signals that show up late if they show up at all.

When your protocol asks questions that touch inflammation, adherence, nutrition, infection risk, or quality of life after systemic therapy, a medical only graph is an incomplete graph. You can still publish. You just cannot see the part of the patient journey that dentistry already documented.

Buyers feel this as vague frustration. Teams know dental "matters." They also know the files they can purchase are usually thin, delayed, unlinked, or locked inside claims codes that were never designed for research grade oral systemic work.

Unlinked dental claims are a commodity

There is no shortage of someone willing to sell you a dental claims extract.

There is a severe shortage of dental data that is:

identity resolved to the same person as the medical record without moving identity across the wrong boundary
longitudinal enough to watch disease and treatment over years, not one billing spike
governed so contributing practices and DSOs keep control of how research use works
scaled across enough sites that a study arm is not a single region anecdote

Unlinked dental rows compete on price. Linked dental medical research data competes on whether your question is even answerable.

If your vendor deck cannot show how dental events join the same patient timeline as medical events, you are not buying oral systemic evidence. You are buying a second silo and hoping an analyst will invent a join later.

The identity problem is the product

The hard part is not "getting dental files." Practices generate them every day.

The hard part is linkage with a clean identity boundary. Research needs patient level continuity. Patients and providers need identity to stay where it belongs. Shortcuts that shove raw identifiers across environments create compliance drag, provider distrust, and datasets that never leave the pilot graveyard.

That is why linkage design is not a footnote. It is the difference between a slide and a study asset.

Bridge Health Syndicate closed that gap. We built the member governed dental data layer for healthcare: de identified dental records linked to medical records at the patient level through the HELIX Protocol (patent pending). Identity never crosses the boundary. Members keep control. Research finally gets the longitudinal oral systemic signal medicine has been missing.

Scarcity is on the supply side

Pharma and AI teams can budget for data. They cannot budget their way into a provider network that refuses to participate, or a patchwork of clinics with no shared research rules.

Scale and governance work because a founding group of dental organizations built the resource together. Founding members set the standards, the research use policy, and the partner categories that later participants inherit. The economics follow the mission: buyers pay for linked real world evidence. Founding contributors own a piece of the asset instead of watching someone else monetize their charts.

If you buy RWD for a living, that structure should change how you rank vendors. Ask who controls contribution. Ask whether dental is first class or bolted on. Ask whether linkage is real or promised in a roadmap slide.

Questions your current stack probably cannot answer

Use these as a stress test on the next renewal:

For a cardiometabolic asset, can you observe periodontal treatment intensity on the same patients as HbA1c trajectories?
For oncology supportive care, can you see dental infection and extraction patterns before systemic complications, not only after a medical claim codes the fallout?
For a payer total cost model, can you connect untreated oral disease to avoidable medical utilization with person level continuity?
For safety, can you detect oral adverse cascades that never appear cleanly in medical only coding?

If the honest answer is no, the gap is not another dashboard. The gap is missing dental depth in the link graph.

What to do with that uncomfortable answer

Stop treating dental as a nice to have annex on a medical purchase.

Demand linked oral systemic coverage as a first class requirement. Treat unlinked dental dumps as commodity filler. Prefer sources where providers are members with governance, not silent upstream farms.

If you want the full story on the Bridge Health Syndicate dental data layer, read https://bhsyndicate.com or email dra@bhsyndicate.com and ask for the data brief.

The mouth was never optional biology. It only became optional data. That era should end.

Rabiel Amirian, DDS
Founder, Bridge Health Syndicate
https://bhsyndicate.com
dra@bhsyndicate.com